Third Rock Ventures

[Third Rock Ventures @ThirdRockV]

Congratulations to @TraceNeuro on their launch with a $101M Series A! We are excited to support a team on a mission to expand the promise of genomic medicine for people living with neurodegenerative diseases.

[Trace Neuroscience @TraceNeuro]

1 in 400 people around the world will be diagnosed w/ #ALS in their lifetime. Meet Trace - on a mission to expand the promise of genomic medicine for those w/ neurodegenerative diseases, re-establishing healthy communication between nerves & muscle cells. https://t.co/UdCt0R5upR

[Third Rock Ventures @ThirdRockV]

Great news for the @AbataTx team, patients, and their families!

[Third Rock Ventures @ThirdRockV]

Congrats to the @moma_tx team! One step closer to helping oncology patients.

[MOMA Therapeutics @moma_tx]

The 1st patient has been dosed in the Phase 1 clinical trial of MOMA-313, a novel, highly potent & selective oral POLq helicase inhibitor, & we've selected our 2nd development candidate, MOMA-341, an oral Werner helicase inhibitor. Read & learn more: https://t.co/ZfPnYoLJJs

[Third Rock Ventures @ThirdRockV]

We are excited by @AbataTx announcement today of a strategic investment from @bmsnews supporting advancement of its Treg cell therapies into clinical development. One step closer to positively impacting patients and their families.

[Third Rock Ventures @ThirdRockV]

Congratulations to Arnav Mehta for receiving the 2024 NextGen Stars award from AACR. So well deserved!
@arnavmehta3

[Third Rock Ventures @ThirdRockV]

We are delighted to announce the expansion of our senior team!
https://t.co/DT81L035Nr

[Life Science Cares @LS_Cares]

And we’re live! Check out the very first episode of our new podcast: Moving Forward, Giving Back. On today’s show, we highlight our 2023 Impact Award Winners - exploring the ways they use the LSC model to support their communities. Tune in here: https://t.co/OgPQYnPDbq!

[Third Rock Ventures @ThirdRockV]

Congrats to the team at @bluebirdbio ! Exciting news for patients and their families

[Genetix Biotherapeutics @genetix_biotx]

#NewsfromtheNest: We are thrilled to announce that the @US_FDA has approved our first gene therapy for patients ages 12 and older living with sickle cell disease who have a history of vaso-occlusive events. Read more in our press release: https://t.co/vSKt4dpmxF [1/1]

[Third Rock Ventures @ThirdRockV]

We had our first farmers market last week in our office to raise money for @LS_Cares and the Hope Lodge - @AmericanCancer! It was a fun time with tasty food to support two great causes.

[Third Rock Ventures @ThirdRockV]

Our collaboration with BrightEdge broadens the impact we can have across the oncology ecosystem. You can learn more about the great work they do below.

[American Cancer Society @AmericanCancer]

BrightEdge is poised to impact the lives of over 1.5 million cancer patients through investments in cancer-focused therapies and technologies. To learn more, read the annual report: https://t.co/u91qm3Fkvg

[Third Rock Ventures @ThirdRockV]

Third Rock is proud to partner with such an impactful organization!

[Life Science Cares @LS_Cares]

Thanks to an incredible list of sponsors and donors, the 2023 #TimmermanTraverse team has cracked their goal of raising $1M to support Life Science Cares' work in the community. And now they're aiming to see just how high they can go! Read more at https://t.co/N1Y7N5fmp5.

[Third Rock Ventures @ThirdRockV]

Congratulations! Great news for mothers and families.

[Sage Therapeutics @SageBiotech]

BREAKING: The FDA has approved our new treatment, developed with @biogen, for women with #postpartumdepression. Learn more: https://t.co/qtkqxHNvDh

[Third Rock Ventures @ThirdRockV]

Congratulations to the team at @Septerna_Inc !

[@Septerna_Inc @Septerna_Inc]

Today we announced a $150M Series B financing, enabling the advancement of our lead program to clinical proof-of-mechanism and marking an important transition for our company. Read today’s news: https://t.co/elb17WzB65

[Third Rock Ventures @ThirdRockV]

We had the pleasure of hosting an inspiring fireside chat with @TracyDixonSalaz and Brad Galer about rare epilepsies and Lennox-Gastaut Syndrome and the high unmet medical need in the precision neuromedicine space.

[Third Rock Ventures @ThirdRockV]

Please join us in welcoming Mary Lynne Hedley to TRV as our newest Venture Partner. She brings valuable leadership and strategic insight across R&D, operations, corporate strategy and business development. We are excited to have her as part of the team!

[Third Rock Ventures @ThirdRockV]

IgniteVC, a new initiative from @IgniteLC in partnership with @BioscienceGroup, has launched to accelerate DEI in life sciences VCs and their portfolio companies by offering practical tools, best practices, and a community of peers.

[Third Rock Ventures @ThirdRockV]

Congrats to Rapport Therapeutics on the announcement of their launch with a $100 million Series A financing. Rapport is dedicated to the discovery and development of precision medicines for neurological disorders and we are excited to be a part of it! https://t.co/VJ5hJ2Ubyc

[Third Rock Ventures @ThirdRockV]

We are excited to be a Founding Partner in the expansion of @ProjectOnramp w/@LS_Cares to support + create paid summer internships for students who are under-resourced and under-represented, helping to bridge the opportunity gap into our industry.

[Life Science Cares @LS_Cares]

We’re on a mission to scale @ProjectOnramp to reach 1,000 students around the country each summer by 2027. Thanks to @ThirdRockV for this multi-year commitment to help us get there! https://t.co/Qrxf2RS20D

[Third Rock Ventures @ThirdRockV]

Congrats to the Abata team on the progress!